OLEA Medical

Olea Medical, created in 2008, is originally a provider of advanced MR and CT perfusion imaging post-processing and designs and markets innovative medical imaging applications significantly improving diagnostic processes and treatment evaluation.

Olea Medical’s current application platform allows a multi-parametric analysis of MR images from various sequences: Diffusion Weighted Imaging, Intra-Voxel Incoherent Motion, Perfusion Weighted Imaging, Diffusion Tensor Imaging, Arterial Spin Labeling, T1 and T2/T2* mapping, dedicated to different organs applications including: neurology, head&neck, breast, prostate, female pelvis, rectum, cardiac, MSK, liver applications, making Olea the only platform covering 95% of the MR needs.

Olea Medical has gained recognition over the years as the leader in advanced post-processing applications for stroke and oncology. A pioneer in Bayesian methods applied to medical imaging post-processing, Olea has already revolutionized perfusion imaging post-processing with real-time, powerful and accurate algorithms for clinical use, in both oncology and stroke diagnosis and therapeutic follow-up. In 2015, Olea Medical was acquired by the Medical branch of Toshiba Group, Toshiba Medical Systems Corporation. The agreement guarantees Olea’s capacity to preserve its strong assets: vendor- neutral software solutions and therefore cross-platform, which is a major asset of the company's solutions for practitioners.

The MARVELOUS project is well in line with the development priorities. MARVELOUS hypothesizes that the improvement of MR imaging through new acquisitions sequences combined with new postprocessing will allow a more accurate evaluation of tissue damage and its determinants, thus helping the decision for reperfusion therapy, and allowing a robust evaluation of patient’s prognosis, requested for an appropriate and personnalized therapeutic management.

Olea Medical will focus on the technical aspects of the development of new algorithms for the post-processing software, their testing and optimization, as well as efforts to reduce computation time, and eventually industrialization issues. Combination of these efforts will provide a new software platform for acute myocardial infarction and for ischemic stroke patients.

The teams members working on the MARVELOUS projet are Christophe Avare, Guillaume Auzias,Timothé Boutelier (team leader), Anca Mitulescu (team leader), Aurélie Peter, Mar Roca, Rémi Rudelle, and Elodie Saccoccio.